BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Phase 1 Data and Plans Phase 2 Study for Lyme Disease Prevention Candidate 

Tonix Pharmaceuticals (NASDAQ: TNXP) announced the presentation of Phase 1 data and plans for an adaptive Phase 2 field study of TNX-4800, a long-acting monoclonal antibody for the prevention of Lyme disease, with initiation expected in the first half of 2027 pending FDA agreement. The candidate, licensed from UMass Chan Medical School, targets Borrelia burgdorferi and […]